Amicus Therapeutics, Inc.
FOLD
Rank in Stocks
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Share Price
$14.49
Last synced: 2026-04-27
Market Cap
$4.55B
Change (1 day)
0.00%
Change (1 year)
80.22%
Country
US
Trade Amicus Therapeutics, Inc. (FOLD)
Category
Healthcare
Operating Margin for Amicus Therapeutics, Inc. (FOLD)
Operating Margin as of October 2026 TTM: 8.00%
According to Amicus Therapeutics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 8.00%. At the end of 2023 the company had an Operating Margin of -19.33%.
Operating Margin history for Amicus Therapeutics, Inc. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 8.00% | 69.85% |
| 2024 | 4.71% | -124.37% |
| 2023 | -19.33% | -68.87% |
| 2022 | -62.09% | -5.12% |
| 2021 | -65.44% | -29.99% |
| 2020 | -93.47% | -43.36% |
| 2019 | -165.03% | -54.20% |
| 2018 | -360.32% | -69.89% |
| 2017 | -1,196.82% | -67.38% |
| 2016 | -3,668.62% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -5,612.83% | -68.25% |
| 2013 | -17,680.72% | 6,049.82% |
| 2012 | -287.50% | 21.10% |
| 2011 | -237.41% | -96.08% |
| 2010 | -6,056.18% | 52,931.35% |
| 2009 | -11.42% | -96.11% |
| 2008 | -293.69% | -88.56% |
| 2007 | -2,567.54% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -95.18% |
US
|
|
| -149.01% | -118.63% |
US
|
|
| 25.57% | -96.80% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.40% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.